Adagene (ADAG) Stock Forecast, Price Target & Predictions
ADAG Stock Forecast
Adagene stock forecast is as follows: an average price target of $5.00 (represents a 43.27% upside from ADAG’s last price of $3.49) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
ADAG Price Target
The average price target for Adagene (ADAG) is $5.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $5.00. This represents a potential 43.27% upside from ADAG's last price of $3.49.
ADAG Analyst Ratings
According to 1 Wall Street analysts, Adagene's rating consensus is 'Buy'. The analyst rating breakdown for ADAG stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Adagene Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 08, 2024 | Matthew Harrison | Morgan Stanley | $5.00 | $2.83 | 76.68% | 43.27% |
The latest Adagene stock forecast, released on Apr 08, 2024 by Matthew Harrison from Morgan Stanley, set a price target of $5.00, which represents a 76.68% increase from the stock price at the time of the forecast ($2.83), and a 43.27% increase from ADAG last price ($3.49).
Adagene Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $5.00 |
| Last Closing Price | $3.49 | $3.49 | $3.49 |
| Upside/Downside | -100.00% | -100.00% | 43.27% |
In the current month, the average price target of Adagene stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Adagene's last price of $3.49. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 08, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
Adagene's last stock rating was published by Morgan Stanley on Apr 08, 2024. The company gave ADAG a "Overweight" rating, the same as its previous rate.
Adagene Financial Forecast
Adagene Revenue Forecast
| Jun 26 | Mar 26 | Jun 25 | Mar 25 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Avg Forecast | - | - | - | $17.50M | - | - |
| High Forecast | - | - | - | $17.50M | - | - |
| Low Forecast | - | - | - | $17.50M | - | - |
| # Analysts | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - |
Adagene's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ADAG's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Adagene EBITDA Forecast
| Jun 26 | Mar 26 | Jun 25 | Mar 25 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - |
| Avg Forecast | - | - | - | $-17.50M | - | - |
| High Forecast | - | - | - | $-17.50M | - | - |
| Low Forecast | - | - | - | $-17.50M | - | - |
| Surprise % | - | - | - | - | - | - |
undefined analysts predict ADAG's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Adagene's previous annual EBITDA (undefined) of $NaN.
Adagene Net Income Forecast
| Jun 26 | Mar 26 | Jun 25 | Mar 25 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - |
| Avg Forecast | $-20.76M | $-18.11M | $-39.75M | $-18.55M | $-17.89M | $-11.48M |
| High Forecast | $-20.76M | $-18.11M | $-39.75M | $-18.55M | $-17.89M | $-11.48M |
| Low Forecast | $-20.76M | $-18.11M | $-39.75M | $-18.55M | $-17.89M | $-11.48M |
| Surprise % | - | - | - | - | - | - |
Adagene's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ADAG's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Adagene SG&A Forecast
| Jun 26 | Mar 26 | Jun 25 | Mar 25 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - |
| Avg Forecast | - | - | - | $61.25M | - | - |
| High Forecast | - | - | - | $61.25M | - | - |
| Low Forecast | - | - | - | $61.25M | - | - |
| Surprise % | - | - | - | - | - | - |
Adagene's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ADAG last annual SG&A of $NaN (undefined).
Adagene EPS Forecast
| Jun 26 | Mar 26 | Jun 25 | Mar 25 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - |
| Avg Forecast | $-0.47 | $-0.41 | $-0.90 | $-0.42 | $-0.41 | $-0.26 |
| High Forecast | $-0.47 | $-0.41 | $-0.90 | $-0.42 | $-0.41 | $-0.26 |
| Low Forecast | $-0.47 | $-0.41 | $-0.90 | $-0.42 | $-0.41 | $-0.26 |
| Surprise % | - | - | - | - | - | - |
According to undefined Wall Street analysts, Adagene's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ADAG previous annual EPS of $NaN (undefined).
Adagene Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.51 | $24.75 | 1539.07% | Buy |
| ANTX | AN2 Therapeutics | $1.04 | $8.75 | 741.35% | Buy |
| AVTE | Aerovate Therapeutics | $1.90 | $13.00 | 584.21% | Hold |
| MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| RZLT | Rezolute | $5.25 | $13.00 | 147.62% | Buy |
| ACRV | Acrivon Therapeutics | $8.91 | $21.50 | 141.30% | Buy |
| ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
| ADAG | Adagene | $3.49 | $5.00 | 43.27% | Buy |
| JANX | Janux Therapeutics | $50.01 | $59.25 | 18.48% | Buy |
| ANAB | AnaptysBio | $40.33 | $36.33 | -9.92% | Buy |
ADAG Forecast FAQ
Is Adagene a good buy?
Yes, according to 1 Wall Street analysts, Adagene (ADAG) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of ADAG's total ratings.
What is ADAG's price target?
Adagene (ADAG) average price target is $5 with a range of $5 to $5, implying a 43.27% from its last price of $3.49. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Adagene stock go up soon?
According to Wall Street analysts' prediction for ADAG stock, the company can go up by 43.27% (from the last price of $3.49 to the average price target of $5), up by 43.27% based on the highest stock price target, and up by 43.27% based on the lowest stock price target.
Can Adagene stock reach $5?
ADAG's average twelve months analyst stock price target of $5 does not support the claim that Adagene can reach $5 in the near future.